ASP-7517

Headline results for the fourth quarter: Revenue: JPY 354.3 billion ($2.6 billion), up 16.6% Loss: JPY 46.1 billion ($345 million)Note: All changes are versus the prior-year period unless otherwise statedWhat the company said:Astellas noted that sales of its main products including Xtandi, Padcev, Xospata showed "steady growth" during the fourth quarter, while revenue from Evenity in Japan also increased.The company explained that the loss in the three-month period was due to an impairment loss of JPY 60.3 billion. Astellas said earlier this month that "considering the sales situation" for Evrenzo in Japan and Europe, it will book an impairment loss of approximately JPY 45 billion, as well as JPY 8.6 billion after terminating the development of FX-322 and JPY 4.7 billion for ending an agreement with Adaptimmune Therapeutics.Other results: Xtandi: JPY 149.3 billion, up 21.6% Betanis, Myrbetriq and Betmiga: JPY 47.5 billion, up 4.8% Prograf: JPY 47.1 billion, up 6.5% Padcev: JPY 11.4 billion, up 58.6% Xospata: JPY 10.3 billion, up 23% Vesicare: JPY 3.5 billion, down 12.7% Evrenzo: JPY 800 million, up 58.5% Full-year revenue: JPY 1.52 trillion, up 17.2% Full-year profit: JPY 98.7 billion, down 20.4%Looking ahead:Astellas expects revenue for fiscal year 2023 of JPY 1.52 trillion ($11.4 billion), broadly in line with the prior 12-month period, with sales of Xtandi reaching nearly JPY 670 billion ($5 billion), up from JPY 661.1 billion ($4.9 billion). Meanwhile, core profit is seen growing 1.5% to JPY 228 billion ($1.7 billion).Pipeline updates:Astellas disclosed that it ended Phase I development of ASP9801 and ASP0739 for cancer, while it also discontinued mid-stage work on ASP7517 in acute myeloid leukaemia and myelodysplastic syndrome, as well as early-stage investigation in solid tumours. The drugmaker added that it also halted Phase I development of ASP8731/ML-0207 for sickle cell disease.($1 = JPY 133.727)